Nuveen Asset Management, LLC Harpoon Therapeutics, Inc. Transaction History

Nuveen Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.78 - $5.02 $90,845 - $256,205	-51,037 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.69 - $7.83 $10,031 - $13,804	1,763 Added 3.58%	51,037 $315,000
Q3 2021 Nov 12, 2021	SELL	$7.88 - $14.0 $540,512 - $960,302	-68,593 Reduced 58.2%	49,274 $431,000
Q2 2021 Aug 16, 2021	BUY	$13.81 - $23.25 $287,248 - $483,600	20,800 Added 21.43%	117,867 $1.64 Million
Q1 2021 May 17, 2021	SELL	$17.65 - $24.16 $28,557 - $39,090	-1,618 Reduced 1.64%	97,067 $2.03 Million
Q4 2020 Feb 16, 2021	BUY	$12.83 - $17.84 $180,569 - $251,080	14,074 Added 16.63%	98,685 $1.64 Million
Q3 2020 Nov 16, 2020	SELL	$11.01 - $18.52 $990,701 - $1.67 Million	-89,982 Reduced 51.54%	84,611 $1.44 Million
Q2 2020 Aug 14, 2020	BUY	$11.11 - $24.72 $315,090 - $701,083	28,361 Added 19.39%	174,593 $2.9 Million
Q1 2020 May 14, 2020	BUY	$10.74 - $16.32 $1.4 Million - $2.13 Million	130,483 Added 828.52%	146,232 $1.69 Million
Q3 2019 Nov 14, 2019	BUY	$10.93 - $17.47 $172,136 - $275,135	15,749 New	15,749 $215,000

353K

Ticker HARP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,106,800
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candi...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.